The US Food and Drug Administration (FDA) has released draft guidance for pharmaceutical manufacturers wishing to replace a color in a drug product. These changes are now viewed as a moderate change ...
The assessment of causation for a potential drug interaction requires thoughtful consideration of the properties of both the object and precipitant drugs, patient-specific factors, and the possible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results